Stock comparison
LeMaitre Vascular
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.51B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 42D | LMAT |
| Benjamin Graham | 81A | 54C | LMAT |
| Philip Fisher | 73B | 50C | LMAT |
| Peter Lynch | 59C | 84A | TGTX |
| Joel Greenblatt | 48D | 55C | TGTX |
| Charlie Munger | 60C | 44D | LMAT |
| Terry Smith | 61C | 37D | LMAT |
Side-by-side metrics
| Metric | LMAT | TGTX |
|---|---|---|
| Market cap | $2.32B | $6.51B |
| P/E (TTM) | 37.1x | 13.3x |
| EV/EBIT | 36.6x | 55.3x |
| ROIC (TTM) | 9.43% | 11.13% |
| Gross margin | 72.39% | 83.04% |
| Net margin | 24.35% | 65.95% |
| Revenue CAGR 5y | 12.75% | 2.1% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 1.3x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Debt / Equity0.5xvs 1.3x+64%
- EV/EBIT36.6xvs 55.3x+34%
TGTX leads on
- Revenue CAGR 5y2.1%vs 12.75%+94%
- Market cap$6.51Bvs $2.32B+64%
- P/E (TTM)13.3xvs 37.1x+64%
- Net margin65.95%vs 24.35%+63%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.